A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

BACKGROUND: Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across a range of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, S., Anandappa, G., Capdevila, J., Dahan, L., Evesque, L., Kim, S., Saunders, M.P., Gilbert, D.C., Jensen, L.H., Samalin, E., Spindler, K.-L., Tamberi, S., Demols, A., Guren, M.G., Arnold, D., Fakih, M., Kayyal, T., Cornfeld, M., Tian, C., Catlett, M., Smith, M., Spano, J.-P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463376/
https://www.ncbi.nlm.nih.gov/pubmed/35816951
http://dx.doi.org/10.1016/j.esmoop.2022.100529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463376/
https://www.ncbi.nlm.nih.gov/pubmed/35816951
http://dx.doi.org/10.1016/j.esmoop.2022.100529

Ejemplares similares